{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:44:04Z","timestamp":1791945844220,"version":"4.3.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>UK studies examining vitiligo burden and vitiligo-related healthcare resource utilization (HCRU) are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To describe the incidence and prevalence of vitiligo, the demographic and clinical characteristics of patients with vitiligo, vitiligo burden, HCRU, incidence of mental health comorbidities and management strategies, including treatment patterns.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study used UK Clinical Practice Research Datalink and Hospital Episode Statistics databases to analyse patients with vitiligo from 1 January 2010 to 31 December 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 17 239 incident patients, mean incidence of vitiligo was 0.16 (2010\u20132021) per 1000 person-years [PY; range 0.10 (2020\u2013COVID-19) to 0.19 (2010\/2013\/2018)]; among 66 217 prevalent patients, prevalence increased from 0.21% (2010) to 0.38% (2021). The most common comorbidities recorded after vitiligo diagnosis were diabetes (19.4%), eczema (8.9%), thyroid disease (7.5%) and rheumatoid arthritis (6.9%). Mental health diagnoses recorded at any time included depression and\/or anxiety (24.6%), depression (18.5%), anxiety (16.0%) and sleep disturbance (12.7%), and recorded after vitiligo diagnosis in 6.4%, 4.4%, 5.5% and 3.9%, respectively. Mental health comorbidities were more common in White (e.g. depression and\/or anxiety 29.0%) than in Black (18.8%) and Asian (16.1%) patients. In adolescents, depression and\/or anxiety was most commonly diagnosed after a vitiligo diagnosis than before (7.4% vs. 1.8%). Healthcare resources were used most frequently in the first year after vitiligo diagnosis (incident cohort), typically dermatology-related outpatient appointments (101.9\/100\u00a0PY) and general practitioner consultations (97.9\/100 PY). In the year after diagnosis, 60.8% of incident patients did not receive vitiligo-related treatment (i.e. topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids or phototherapy), increasing to 82.0% the next year; median time from diagnosis to first treatment was 34.0\u2005months (95% confidence interval 31.6\u201336.4). Antidepressants and\/or anxiolytics were recorded for 16.7% of incident patients in the year after diagnosis. In 2019, 85.0% of prevalent patients did not receive vitiligo-related treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Most patients were not on vitiligo-related treatments within a year of diagnosis, with the time to first treatment exceeding 2\u2005years, suggesting that vitiligo may be dismissed as unimportant. New effective treatments, early initiation and psychological intervention and support are needed to reduce the vitiligo burden on patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae133","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T15:56:48Z","timestamp":1711555008000},"page":"216-224","source":"Crossref","is-referenced-by-count":22,"title":["Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5776-1466","authenticated-orcid":false,"given":"Viktoria","family":"Eleftheriadou","sequence":"first","affiliation":[{"name":"Royal Wolverhampton NHS Trust , Wolverhampton , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Delattre","sequence":"additional","affiliation":[{"name":"Incyte Biosciences International , Morges , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shala","family":"Chetty-Mhlanga","sequence":"additional","affiliation":[{"name":"IQVIA Real World Solutions , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lee","sequence":"additional","affiliation":[{"name":"IQVIA Real World Evidence Solutions , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Girardat-Rotar","sequence":"additional","affiliation":[{"name":"IQVIA Real World Solutions , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftekhar","family":"Khan","sequence":"additional","affiliation":[{"name":"University of Warwick , Coventry , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Mathew","sequence":"additional","affiliation":[{"name":"Incyte Biosciences UK Ltd , Leatherhead , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-7222","authenticated-orcid":false,"given":"Andrew R","family":"Thompson","sequence":"additional","affiliation":[{"name":"Cardiff and Vale University Health Board and Cardiff University, South Wales Clinical Psychology Training Programme , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"2024071611234491300_ljae133-B1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"2024071611234491300_ljae133-B2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2024071611234491300_ljae133-B3","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/jdv.18257","article-title":"Vitiligo prevalence and quality of life among adults in Europe, Japan, and the USA","volume":"36","author":"Bibeau","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024071611234491300_ljae133-B4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/CLEP.S304155","article-title":"Epidemiology of vitiligo \u2013 a dual population-based approach","volume":"13","author":"Mohr","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2024071611234491300_ljae133-B5","doi-asserted-by":"crossref","first-page":"e338-9","DOI":"10.1111\/bjd.15933","article-title":"Quality of life in people with vitiligo: a systematic review and meta-analysis","volume":"177","author":"Morrison","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024071611234491300_ljae133-B6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024071611234491300_ljae133-B7","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaad.2019.07.036","article-title":"Comorbid diseases of vitiligo: a 10-year cross-sectional retrospective study of an urban US population","volume":"82","author":"Hadi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024071611234491300_ljae133-B8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000354607","article-title":"Comorbidities associated with \u00advitiligo: a ten-year retrospective study","volume":"227","author":"Sheth","year":"2013","journal-title":"Dermatology"},{"key":"2024071611234491300_ljae133-B9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16049","article-title":"The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis","volume":"178","author":"Osinubi","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024071611234491300_ljae133-B10","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1192\/bjo.2022.591","article-title":"The mental health associations of vitiligo: UK population-based cohort study","volume":"8","author":"Thompson","year":"2022","journal-title":"BJPsych Open"},{"key":"2024071611234491300_ljae133-B11","author":"Baker"},{"key":"2024071611234491300_ljae133-B12","author":"Office for National Statistics (ONS)"},{"key":"2024071611234491300_ljae133-B13","doi-asserted-by":"crossref","first-page":"e0163806","DOI":"10.1371\/journal.pone.0163806","article-title":"The prevalence of vitiligo: a meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLOS ONE"},{"key":"2024071611234491300_ljae133-B14","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jdv.16927","article-title":"Patients\u2019 perspective on current treatments and demand for novel treatments in vitiligo","volume":"35","author":"Narayan","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024071611234491300_ljae133-B15","author":"Office for National Statistics (ONS)"},{"key":"2024071611234491300_ljae133-B16","first-page":"4","article-title":"Smoking and skin disease","volume":"15","author":"Thomsen","year":"2010","journal-title":"Skin Therapy Lett"},{"key":"2024071611234491300_ljae133-B17","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/2229-5178.142493","article-title":"Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: a case-control study","volume":"5","author":"Gopal","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"2024071611234491300_ljae133-B18","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/jdv.12870","article-title":"Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan","volume":"29","author":"Chen","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024071611234491300_ljae133-B19","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s13555-023-01001-2","article-title":"Comorbidity burden among patients with vitiligo in the United States: a large-scale retrospective claims database analysis","volume":"13","author":"Ezzedine","year":"2023","journal-title":"Dermatol Ther (Heidelb"},{"key":"2024071611234491300_ljae133-B20","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1111\/jdv.19447","article-title":"Vitiligo patient population and disease burden in France: VIOLIN study results from the CONSTANCES cohort","volume":"37","author":"Ezzedine","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024071611234491300_ljae133-B21","author":"Office for National Statistics (ONS)"},{"key":"2024071611234491300_ljae133-B22","author":"Baker"},{"key":"2024071611234491300_ljae133-B23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2133.2010.09828.x","article-title":"Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo","volume":"163","author":"Thompson","year":"2010","journal-title":"Br J Dermatol"},{"key":"2024071611234491300_ljae133-B24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1365-2230.2009.03765.x","article-title":"Vitiligo is more than skin deep: a survey of members of the Vitiligo Society","volume":"35","author":"Talsania","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"2024071611234491300_ljae133-B25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjd.20596","article-title":"British Association of Dermatologists guidelines for the management of people with vitiligo 2021","volume":"186","author":"Eleftheriadou","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024071611234491300_ljae133-B26","doi-asserted-by":"crossref","first-page":"e11-18","DOI":"10.1016\/j.jaad.2012.01.038","article-title":"Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL)","volume":"69","author":"Lilly","year":"2013","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae133\/57448579\/ljae133.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/2\/216\/58554269\/ljae133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/2\/216\/58554269\/ljae133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T11:24:20Z","timestamp":1721129060000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/2\/216\/7635728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3,27]]},"published-print":{"date-parts":[[2024,7,16]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae133","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,3,27]]}}}